Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ida Hude Dragičević"'
Autor:
Ida Hude Dragičević, Sandra Bašić-Kinda, Helena Markotić, Martina Morić-Perić, Dino Dujmović, Ivo Radman, Barbara Dreta, Snježana Dotlić, Ivana Ilić, Lea Galunić Bilić, Margareta Dobrenić, Marko Kralik, Igor Aurer
Publikováno v:
Medicina, Vol 60, Iss 3, p 430 (2024)
Background and Objectives: eBEACOPP is the most effective chemotherapy regimen for younger patients with early unfavorable (EU) and advanced-stage (AS) Hodgkin lymphoma (HL), albeit with significant toxicities. The 14-day/cycle prednisone course cont
Externí odkaz:
https://doaj.org/article/aa353efaeaa543cd9c08ecf8a014fba1
Autor:
Ida Hude Dragičević, Sandra Bašić-Kinda, Dino Dujmović, Ivo Radman, Barbara Dreta, Sandra Dotlić, Lea Galunić-Bilić, Margareta Dobrenić, Marko Kralik, Pavle Rončević, Igor Aurer
Publikováno v:
HemaSphere, Vol 6, Pp 8-8 (2022)
Externí odkaz:
https://doaj.org/article/cbf2c62b30d0467a8e3ae6b76a4ca891
Autor:
Dubravka Šipuš, Luka Perčin, Anica Milinković, Dora Fabijanović, Ivo Planinc, Marijan Pašalić, Nina Jakuš, Hrvoje Jurin, Jure Samardžić, Boško Skorić, Maja Čikeš, Ida Hude Dragičević, Davor Miličić, Daniel Lovrić
Publikováno v:
Cardiologia Croatica
Volume 18
Issue 5-6
Volume 18
Issue 5-6
Autor:
Majda Vučić, Liborija Lugović-Mihić, Krešimir Rotim, Ida Hude Dragičević, Josip Mihić, Marta Borić
Publikováno v:
Acta Clinica Croatica
Acta clinica Croatica
Volume 58.
Issue 3.
Acta clinica Croatica
Volume 58.
Issue 3.
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Clinically useful molecular markers that help predict response to therapy and prognosis are still rare. The research was conducted in 55 pat